Interferon and Lamivudine Vs. Interferon for Hepatitis B E Antigen-positive Hepatitis B Treatment: Meta-analysis of Randomized Controlled Trials

Overview

Journal Liver Int

Specialty Gastroenterology

Date 2007 Oct 9

PMID 17919229

Citations 4

Authors

Dan Rudin

Sooraj M Shah

Alexander Kiss

Robert V Wetz

Vincent M Sottile

Affiliations

Soon will be listed here.

Abstract

Aims: To compare interferon monotherapy with its combination with lamivudine for hepatitis B e antigen (HBeAg)-positive hepatitis B treatment.

Methods: Two independent researchers identified pertinent randomized controlled trials. The trials were evaluated for methodological quality and heterogeneity. Rates of sustained virological and biochemical responses, and HBeAg clearance and seroconversion were used as primary efficacy measures. Quantitative meta-analyses were conducted to assess differences between groups for conventional and pegylated interferon, and overall.

Results: Greater sustained virological, biochemical and seroconversion rates were observed with addition of lamivudine to conventional [odds ratio (OR)=3.1, 95% confidence intervals (CI) (1.7-5.5), P<0.0001, OR=1.8, 95% CI (1.2-2.7), P=0.007 and OR=1.8, 95% CI (1.1-2.8), P=0.01 respectively], although not pegylated [OR=1.1, 95% CI (0.5-2.3), P=0.8, OR=1.0, 95% CI (0.7-1.3), P=0.94, and OR=0.9, 95% CI (0.6-1.2), P=0.34 respectively] interferon-alpha, with no significant affect on HBeAg clearance rates [OR=1.6, 95% CI (0.9-2.7), P=0.09, and OR=0.8, 95% CI (0.6-1.1), P=0.26 respectively]. Excluding virological response (P<0.001), pegylated interferon monotherapy and conventional interferon and lamivudine combination therapy were similarly efficacious (P>0.05), with the former studied in harder to treat patients, as evidenced by the superior virological response observed with conventional as compared with pegylated interferon monotherapy (P<0.0001).

Conclusion: In comparable populations, pegylated interferon monotherapy is likely to be equally or more efficacious than conventional interferon and lamivudine combination therapy, thus constituting the treatment of choice, with no added benefit with lamivudine addition. However, when conventional interferon is used, its combination with lamivudine should be considered.

Citing Articles

Use of Aptamers as Diagnostics Tools and Antiviral Agents for Human Viruses.

Gonzalez V, Martin M, Fernandez G, Garcia-Sacristan A Pharmaceuticals (Basel). 2016; 9(4).

PMID: 27999271 PMC: 5198053. DOI: 10.3390/ph9040078.

A Meta-Analysis of the Efficacy of Interferon Monotherapy or Combined with Different Nucleos(t)ide Analogues for Chronic Hepatitis B.

Zhou J, Wu X, Wei W, You H, Jia J, Kong Y Int J Environ Res Public Health. 2016; 13(5).

PMID: 27455288 PMC: 4962271. DOI: 10.3390/ijerph13070730.

Inhibition of alpha interferon (IFN-α)-induced microRNA-122 negatively affects the anti-hepatitis B virus efficiency of IFN-α.

Hao J, Jin W, Li X, Wang S, Zhang X, Fan H J Virol. 2012; 87(1):137-47.

PMID: 23055569 PMC: 3536426. DOI: 10.1128/JVI.01710-12.

Viral hepatitis in elderly haemodialysis patients: current prevention and management strategies.

Girndt M Drugs Aging. 2008; 25(10):823-40.

PMID: 18808207 DOI: 10.2165/00002512-200825100-00002.

References

Jang M, Chung Y, Choi M, Kim J, Ryu S, Shin J . Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy. J Gastroenterol Hepatol. 2004; 19(12):1363-8. DOI: 10.1111/j.1440-1746.2004.03464.x. View

Lai C, Ratziu V, Yuen M, Poynard T . Viral hepatitis B. Lancet. 2003; 362(9401):2089-94. DOI: 10.1016/S0140-6736(03)15108-2. View

Hui C, Lau G . Peginterferon-alpha2a (40 kDa) (Pegasys) for hepatitis B. Expert Rev Anti Infect Ther. 2005; 3(4):495-504. DOI: 10.1586/14787210.3.4.495. View

Lau G, Tsiang M, Hou J, Yuen S, Carman W, Zhang L . Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology. 2000; 32(2):394-9. DOI: 10.1053/jhep.2000.9143. View

Lim S, Krastev Z, Ng T, Mechkov G, Kotzev I, Chan S . Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother. 2006; 50(5):1642-8. PMC: 1472200. DOI: 10.1128/AAC.50.5.1642-1648.2006. View

Lai C, Leung N, Teo E, Tong M, Wong F, Hann H . A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005; 129(2):528-36. DOI: 10.1016/j.gastro.2005.05.053. View

Perrillo R . Current treatment of chronic hepatitis B: benefits and limitations. Semin Liver Dis. 2005; 25 Suppl 1:20-8. DOI: 10.1055/s-2005-915647. View

van Zonneveld M, Zondervan P, Cakaloglu Y, Simon C, Akarca U, So T . Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int. 2006; 26(4):399-405. DOI: 10.1111/j.1478-3231.2006.01257.x. View

Lau G . Hepatitis B infection in China. Clin Liver Dis. 2001; 5(2):361-79. DOI: 10.1016/s1089-3261(05)70170-7. View

10.

Karabay O, Tamer A, Tahtaci M, Vardi S, Celebi H . Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. J Microbiol Immunol Infect. 2005; 38(4):262-6. View

11.

Jacobson I . Therapeutic options for chronic hepatitis B: considerations and controversies. Am J Gastroenterol. 2006; 101 Suppl 1:S13-8. DOI: 10.1111/j.1572-0241.2006.00477.x. View

12.

Peters M, Hann Hw H, Martin P, Heathcote E, Buggisch P, Rubin R . Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2003; 126(1):91-101. DOI: 10.1053/j.gastro.2003.10.051. View

13.

Shepherd J, Jones J, Takeda A, Davidson P, Price A . Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess. 2006; 10(28):iii-iv, xi-xiv, 1-183. DOI: 10.3310/hta10280. View

14.

Ayaz C, Celen M, Colak H, Hosoglu S, Geyik M . Comparison of lamivudine and alpha-interferon combination with alpha-interferon alone in the treatment of HBeAg-positive chronic hepatitis B. Indian J Gastroenterol. 2006; 25(2):71-3. View

15.

Barbaro G, ZECHINI F, Pellicelli A, Francavilla R, Scotto G, Bacca D . Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol. 2001; 35(3):406-11. DOI: 10.1016/s0168-8278(01)00145-3. View

16.

Marcellin P, Lau G, Bonino F, Farci P, Hadziyannis S, Jin R . Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351(12):1206-17. DOI: 10.1056/NEJMoa040431. View

17.

Chan H, Hui A, Wong V, Chim A, Wong M, Jao-Yiu Sung J . Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology. 2005; 41(6):1357-64. DOI: 10.1002/hep.20695. View

18.

Perrillo R, Hann H, Mutimer D, Willems B, Leung N, Lee W . Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2003; 126(1):81-90. DOI: 10.1053/j.gastro.2003.10.050. View

19.

Malik A, Lee W . Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med. 2000; 132(9):723-31. DOI: 10.7326/0003-4819-132-9-200005020-00007. View

20.

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View